Metaverse: Der Sprung in die virtuelle Welt? - Investieren Sie jetzt mit dem Partizipationszertifikat in Unternehmen aus dem Metaverse Umfeld!-w-
13.10.2021 17:50

Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?

Folgen
Werbung
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One company value investors might notice is GlaxoSmithKline (GSK). GSK is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock holds a P/E ratio of 12.69, while its industry has an average P/E of 14.35. GSK's Forward P/E has been as high as 14.45 and as low as 11.02, with a median of 12.77, all within the past year.Another notable valuation metric for GSK is its P/B ratio of 3.41. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 5.62. Over the past year, GSK's P/B has been as high as 3.95 and as low as 3.15, with a median of 3.56.Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. GSK has a P/S ratio of 2.35. This compares to its industry's average P/S of 3.64.Finally, our model also underscores that GSK has a P/CF ratio of 8.21. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 19.19. Within the past 12 months, GSK's P/CF has been as high as 12.79 and as low as 8.05, with a median of 9.05.These figures are just a handful of the metrics value investors tend to look at, but they help show that GlaxoSmithKline is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, GSK feels like a great value stock at the moment.Zacks Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here.
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu GlaxoSmithKline plc (GSK)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu GlaxoSmithKline plc (GSK)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
24.11.2021GlaxoSmithKline NeutralUBS AG
23.11.2021GlaxoSmithKline BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
22.11.2021GlaxoSmithKline NeutralUBS AG
22.11.2021GlaxoSmithKline NeutralUBS AG
11.11.2021GlaxoSmithKline BuyGoldman Sachs Group Inc.
23.11.2021GlaxoSmithKline BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
11.11.2021GlaxoSmithKline BuyGoldman Sachs Group Inc.
08.11.2021GlaxoSmithKline BuyGoldman Sachs Group Inc.
27.10.2021GlaxoSmithKline BuyGoldman Sachs Group Inc.
27.10.2021GlaxoSmithKline BuyJefferies & Company Inc.
24.11.2021GlaxoSmithKline NeutralUBS AG
22.11.2021GlaxoSmithKline NeutralUBS AG
22.11.2021GlaxoSmithKline NeutralUBS AG
10.11.2021GlaxoSmithKline NeutralUBS AG
08.11.2021GlaxoSmithKline NeutralJP Morgan Chase & Co.
28.10.2021GlaxoSmithKline UnderperformCredit Suisse Group
28.10.2021GlaxoSmithKline UnderweightBarclays Capital
29.07.2021GlaxoSmithKline UnderperformCredit Suisse Group
29.07.2021GlaxoSmithKline UnderweightBarclays Capital
19.07.2021GlaxoSmithKline UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für GlaxoSmithKline plc (GSK) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Neue Virussorgen: DAX geht tiefrot ins Wochenende -- Ausverkauf in den USA -- Lufthansa fliegt vorerst weiter nach Südafrika -- Tesla verzichtet auf staatliche Förderung -- Software AG, K+S im Fokus

Apple macht iPhone in der Türkei über Nacht mehr als 25 Prozent teurer. Ocugen-Aktie: FDA stoppt Covaxin-Impfstoff. BioNTech prüft Wirksamkeit seines Impfstoffs gegen neue Corona-Variante. Nextcloud legt Beschwerde gegen Microsoft beim Bundeskartellamt ein. Kryptowährungen geben wegen neuer Virusvariante kräftig nach. Deutsche Bank: Entscheidend ob Impfstoffe gegen Variante wirken.

Umfrage

Sind Sie in Kryptowährungen wie Bitcoin, Ether & Co. investiert?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln